Browsing by Subject "Psychopharmacology"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough?
    (Elsevier, 2018-02) Hathaway, Elizabeth E.; Walkup, John T.; Strawn, Jeffrey R.; Graduate Medical Education, IU School of Medicine
    Anxiety and depressive disorders are common in the pediatric primary care setting, and respond to both psychotherapeutic and psychopharmacologic treatment. However, there are limited data regarding the optimal treatment duration. This article systematically reviews guidelines and clinical trial data related to antidepressant treatment duration in pediatric patients with depressive and anxiety disorders. The extant literature suggests 9-12 months of antidepressant treatment for youth with major depressive disorder. For generalized, separation and social anxiety disorders, 6-9 months of antidepressant treatment may be sufficient, though many clinicians extend treatment to 12 months based on extrapolation of data from adults with anxiety disorders. Such extended treatment periods may decrease the risk of long-term morbidity and recurrence; however, the goal of treatment is ultimately remission, rather than duration of antidepressant pharmacotherapy. Moreover, while evidence-based guidelines represent a starting point, appropriate treatment duration varies and patient-specific response, psychological factors, and timing of discontinuation must be considered for individual pediatric patients.
  • Thumbnail Image
    Item
    Intersection of Minority Health, Health Disparities, and Social Determinants of Health With Psychopharmacology and Substance Use
    (American Psychological Association, 2021) Lopez-Vergara, Hector I.; Zapolski, Tamika C. B.; Leventhal, Adam M.; Psychology, School of Science
    These articles provide a window into the breadth of issues at the intersection of MHDS with psychopharmacology and substance use. Integrating the fields of psychopharmacology and basic behavioral addictions science with research on MHDS is not only of public health importance, but can help further elucidate our understanding of human behavior in all of its complexity. As demonstrated here, a better understanding of the synergy between societal context(s) and individual-level processes can lead to interventions tailored to specific risk and resilience factors; interventions that are personalized and contextualized have the potential to improve the health of our society. We are very grateful to the authors for their contributions to this special issue. We hope that professionals from various disciplines who read this special issue become inspired to bridge psychopharmacological and social determinants perspectives in their own work, and, in turn, accelerate scientific progress within each field.